(MedPage Today) — CHICAGO — Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to significantly longer disease-free survival (DFS) as compared with observation, a randomized trial showed.
DFS…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115810
Author :
Publish date : 2025-05-31 12:00:00
Copyright for syndicated content belongs to the linked Source.
